ProtoKinetix completes sale of AAGP tool for protecting delicate cells in research

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), announces today that it has completed the sale of (AAGP™) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP™ family of molecules to the medical research community. This community includes major pharmaceutical corporations, universities, foundations, private laboratories, and government agencies.

Due to the extremely delicate nature and high cost of producing cells typically used in medical research, the protection and defense of these cells is a critical priority in any successful research program. AAGP™ has demonstrated superior properties of protection in the face of a wide range of hostilities. Data shows that the addition of this family of molecules will substantially increase the viability and longevity of these critical cells, resulting in a cost reducing, shorter research cycle.

Whilst the primary focus of ProtoKinetix internally is the development of disease specific therapeutic agents, this opportunity to commence cash flow will enhance the Company's ability to expand its therapeutic targets.